| Literature DB >> 30145112 |
Reema Railkar1, Piyush K Agarwal2.
Abstract
There are limited treatment options for patients with recurrent non-muscle-invasive bladder cancer. In this report, we will talk about the history of photodynamic therapy; although it showed encouraging therapeutic results, it was largely abandoned due to toxicity or bystander effects on normal cells. Monoclonal antibody-conjugates represent an emerging therapeutic approach for malignancies that improves upon tumor specificity. The use of a monoclonal antibody-photosensitizer conjugate is a more selective method of delivering light therapy and has been termed "photoimmunotherapy", which we will discuss in the last part of this report.Entities:
Keywords: 5-Aminolevulinic acid; BCG-refractory NMIBC; Bladder cancer; Hematoporphyrin; Hexaminolevulinic acid; PDT; PIT; Photodynamic therapy; Photoimmunotherapy; Urothelial cancer
Mesh:
Substances:
Year: 2018 PMID: 30145112 DOI: 10.1016/j.euf.2018.08.005
Source DB: PubMed Journal: Eur Urol Focus ISSN: 2405-4569